Unnamed: 0,title,date,stock,sentiment
1108015.0,Retrophin Announces Proposed Public Offering of Common Stock; No Terms Disclosed,2020-06-08 16:01:00-04:00,RTRX,negative
1108016.0,"BMO Capital Maintains Outperform on Retrophin, Raises Price Target to $34",2020-05-12 10:31:00-04:00,RTRX,neutral
1108017.0,"Retrophin Q1 Adj. EPS $(0.200) Beats $(0.670) Estimate, Sales $47.800M Beat $43.430M Estimate",2020-05-11 16:11:00-04:00,RTRX,neutral
1108018.0,Retrophin Announces Enrollment of First 190 Patients in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis,2020-03-09 08:07:00-04:00,RTRX,neutral
1108019.0,"Barclays Downgrades Retrophin to Equal-Weight, Announces $19 Price Target",2020-02-25 05:28:00-05:00,RTRX,neutral
1108020.0,"Retrophin Q4 EPS $(0.70) Misses $(0.64) Estimate, Sales $46.688M Beat $46.02M Estimate",2020-02-24 16:02:00-05:00,RTRX,negative
1108021.0,Retrophin Sees Q4 Net Product Sales of $47M,2020-01-13 07:47:00-05:00,RTRX,neutral
1108022.0,"Retrophin Q3 EPS $(0.66) Beats $(1.05) Estimate, Sales $44.4M Miss $45.3M Estimate",2019-10-30 16:05:00-04:00,RTRX,negative
1108023.0,"Canaccord Genuity Maintains Buy on Retrophin, Lowers Price Target to $23",2019-08-23 08:03:00-04:00,RTRX,negative
1108024.0,"BMO Capital Maintains Outperform on Retrophin, Lowers Price Target to $33",2019-08-23 07:56:00-04:00,RTRX,negative
1108025.0,"Barclays Maintains Overweight on Retrophin, Lowers Price Target to $20",2019-08-23 07:44:00-04:00,RTRX,negative
1108026.0,"Nomura Maintains Buy on Retrophin, Lowers Price Target to $33",2019-08-23 07:40:00-04:00,RTRX,negative
1108027.0,Retrophin shares are trading lower after the company reported its Phase 3 FORT study of Fosmetpantotenate did not meet its primary or secondary endpoints.,2019-08-22 07:56:00-04:00,RTRX,neutral
1108028.0,Retrophin's Phase 3 FORT Study of Fosmetpantotnate in Patients with PKAN Did Not Meet its Primary or Secondary Endpoints,2019-08-22 06:11:00-04:00,RTRX,neutral
1108029.0,"Retrophin Q2 EPS $(0.58) Beats $(0.64) Estimate, Sales $44.707M Beat $43.01M Estimate",2019-08-06 16:10:00-04:00,RTRX,neutral
1108030.0,Retrophin Announces FDA Approval Of THIOLA EC 100mg And 300mg Tablets For The Treatment Of Cystinuria,2019-06-28 16:38:00-04:00,RTRX,positive
1108031.0,Retrophin Announces Cooperative Research And Development Agreement With NCATS And Alagille Syndrome Alliance To Identify Potential Therapeutics For Alagille Syndrome,2019-06-18 16:32:00-04:00,RTRX,positive
1108032.0,Retrophin Announces Top-Line Results From Pivotal Phase 3 Fort Study In Pkan On-Track For 3Q 2019; Announces Enrollment Ongoing In Phase 3 Clinical Trials Of Sparsentan For Patients With Rare Nephropathies Fsgs And Igan,2019-05-07 16:54:00-04:00,RTRX,neutral
1108033.0,"Retrophin Q1 EPS $(0.63) Misses $(0.59) Estimate, Sales $39.6M Miss $40.99M Estimate",2019-05-07 16:52:00-04:00,RTRX,negative
1108034.0,"Barclays Initiates Coverage On Retrophin with Overweight Rating, Announces $36 Price Target",2019-04-22 07:30:00-04:00,RTRX,negative
1108035.0,Retrophin shares are trading higher after the company beat Q4 EPS estimates.,2019-02-27 10:31:00-05:00,RTRX,positive
1108036.0,"Retrophin Q4 EPS $(0.21) Beats $(0.48) Estimate, Sales $43.77M Miss $44.53M Estimate",2019-02-26 17:04:00-05:00,RTRX,negative
1108037.0,"UPDATE: Canaccord Genuity On Retrophin 'Sees 1H19 proof-of-concept data for CNSA-001 in PKU patients, (2) April'19 data from SONAR study of atrasentan in diabetic nephropathy, and (3) June 30 PDUFA for a new formulation of Thiola' As Catalysts In 1H19",2019-02-12 10:10:00-05:00,RTRX,neutral
1108038.0,"Canaccord Genuity Views 'recent weakness in RTRX shares as offering an attractive buying opportunity into several 1H19 catalysts'; Maintains Buy, $36 Target",2019-02-12 10:08:00-05:00,RTRX,positive
1108039.0,"Stocks Which Set New 52-Week Low Mon., Jan. 28, 2019",2019-01-28 15:33:00-05:00,RTRX,negative
1108040.0,Retrophin Sees 2019 Product Sales of $164M,2019-01-07 07:23:00-05:00,RTRX,neutral
1108041.0,Retrophin Names Eric Dube President And CEO,2019-01-03 16:30:00-05:00,RTRX,neutral
1108042.0,Retrophin Reports Dosing Of First Patient In Pivotal Phase 3 PROTECT Study Of Sparsentan For Treatment Of IgA Nephropathy,2018-12-27 08:06:00-05:00,RTRX,positive
1108043.0,Retrophin Completes Enrollment Of Pivotal Phase 3 FORT Study Of Fosmetpantotenate In PKAN,2018-12-20 08:08:00-05:00,RTRX,neutral
1108044.0,"UPDATE: Nomura Recommends 'owning RTRX into 3 potentially positive data FY19
readouts starting in 1H19 that may support 3 approvals over the next 2 years'",2018-11-19 11:15:00-05:00,RTRX,positive
1108045.0,"Nomura Initiates Coverage On Retrophin with Buy Rating, Announces $57 Price Target",2018-11-19 08:40:00-05:00,RTRX,neutral
1108046.0,Retrophin Announces FDA Acceptance of its New Drug Application for Thiola in the Treatment of Cystinuria,2018-11-12 07:09:00-05:00,RTRX,positive
1108047.0,"Retrophin Q3 EPS $(0.68) Misses $(0.46) Estimate, Sales $40.706M Miss $44.42M Estimate",2018-11-01 16:07:00-04:00,RTRX,negative
1108048.0,"Jefferies Initiates Coverage On Retrophin with Buy Rating, Announces $44 Price Target",2018-10-30 10:48:00-04:00,RTRX,neutral
1108049.0,Retrophin Reports Publication Of Phase 2 DUET Study Of Sparsentan For Treatment Of Focal Segmental Glomerulosclerosis In Journal Of American Society Of Nephrology,2018-10-25 16:41:00-04:00,RTRX,neutral
1108050.0,"Stocks Which Set New 52-Week High Friday, August 31",2018-09-04 10:29:00-04:00,RTRX,neutral
1108051.0,"Canaccord Genuity Initiates Coverage On Retrophin with Buy Rating, Announces $36 Price Target",2018-08-17 07:44:00-04:00,RTRX,neutral
1108052.0,Retrophin Names Noah Rosenberg CMO,2018-07-30 16:31:00-04:00,RTRX,neutral
1108053.0,"Retrophin CEO Stephen Aselage To Retire, Will Remain In His Role Until A Replacement Is Appointed",2018-07-26 16:39:00-04:00,RTRX,neutral
1108054.0,"Retrophin Q2 Adj. EPS $(0.25) Beats $(0.35) Estimate, Sales $41.3M Miss $43.22M Estimate",2018-07-26 16:39:00-04:00,RTRX,negative
1108055.0,Retrophin Reports US PTO Issued New Patent Covering Co.'s Product Candidate Sparsentan,2018-06-14 08:03:00-04:00,RTRX,neutral
1108056.0,"Retrophin Reports Independent Data Monitoring Committee's Review Of Safety Data Supports Continuing With Current Phase 3 FORT Study As Planned, Top-Line Data Due Second Half Of 2019",2018-06-04 08:05:00-04:00,RTRX,positive
1108057.0,Retrophin Reports Q1 2018  EPS of -0.14 vs -0.45 Est Revenue of $38.4M vs $39.32M Est,2018-05-01 16:04:00-04:00,RTRX,neutral
1108058.0,Retrophin Initiates Pivotal Phase 3 Clinical Trial of Sparsentan for the Treatment of Focal Segmental Glomerulosclerosis,2018-04-03 08:06:00-04:00,RTRX,neutral
1108059.0,"Retrophin Reports Q4 Adj. EPS $0.07 vs $(0.19) Est., Sales $42.2M vs $41.7M Est.",2018-02-27 16:43:00-05:00,RTRX,neutral
1108060.0,"Retrophin Sees Q4 Sales ~$42M vs $41.7M Est., Prelim. FY17 Sales ~$155M vs $154M Est.,",2018-01-08 07:02:00-05:00,RTRX,neutral
1108061.0,"Retrophin, Censa Pharma Report Strategic Collaboration To Advance CNSA-001 For treatment Of PKU",2018-01-05 08:00:00-05:00,RTRX,neutral
1108062.0,"Retrophin Reports Q3 EPS $(0.46) vs $(0.25) Est., Sales $40.3M vs $40.5M Est.",2017-11-07 17:54:00-05:00,RTRX,neutral
1108063.0,Retrophin Announces Child Neurology Society Presentation Includes Data Suggesting 30-Month Treatment With Fosmetpantotenate Was Associated With Persistent Improvement In Patient Functioning,2017-10-05 16:34:00-04:00,RTRX,positive
1108064.0,Retrophin Announces a Cooperative Research and Development Agreement with NCATS and NGLY1.org to Identify Potential Small Molecule Therapeutics for NGLY1 Deficiency,2017-09-05 08:18:00-04:00,RTRX,positive
1108065.0,Retrophin Reports Q2 Adj. EPS $0.03 vs $(0.22) Sales $38.8M vs $37.36M,2017-08-09 16:06:00-04:00,RTRX,neutral
1108066.0,"Retrophin Begins Patient Dosing in International, Registrational Phase 3 Trial of RE-024 in PKAN",2017-07-25 08:05:00-04:00,RTRX,neutral
1108067.0,"Retrophin Reports Expansion of IP Estate for Sparsentan; Received New Patents in US, Europe",2017-06-01 08:07:00-04:00,RTRX,neutral
1108068.0,"Retrophin Reports Increase Of IP Estate For Sparsentan With Newly Issued Patents In U.S., Europe",2017-06-01 08:07:00-04:00,RTRX,positive
1108069.0,"Retrophin Reports Q1 Adj. EPS $0.01 vs $(0.26) Est., Sales $33.62M vs $36.2M Est.",2017-05-04 16:56:00-04:00,RTRX,neutral
1108070.0,William Blair Initiates Coverage On Retrophin With Outperform,2017-04-06 07:09:00-04:00,RTRX,neutral
1108071.0,"8-K from Ligand Pharma Highlights Co. is Eligible to Receive $1.6M Upon Initiation of Retrophin's Phase 3 Trial o f Sparsentan, ~$5.99M Upon Filing of NDA in FSGS, Potential Net Milestones of $65M+ in the Future, 9% Net Royalties",2017-03-03 09:09:00-05:00,RTRX,neutral
1108072.0,"TheStreet's Adam Feuerstein Tweets '$RTRX Sparsentan ph3 study will include interim analysis of proteinuria, which if +, can serve as accelerated approval endpoint. Compromise.'",2017-03-01 16:15:00-05:00,RTRX,positive
1108073.0,Martin Shkreli Comments on Retrophin: 'Retrophin is so poorly run. Steve Aselage has no idea what he is doing. I can't believe I let this guy steal my company from underneath my feet. What a loser.',2017-03-01 16:13:00-05:00,RTRX,negative
1108074.0,Retrophin Reports Q4 Non-GAAP EPS $0.00 vs. YoY $0.06 Sales $37.32M vs. $35.95M Est.,2017-03-01 16:03:00-05:00,RTRX,neutral
1108075.0,Retrophin Says Phase 3 Trial Of sparsentan To Start In 2H 2017,2017-03-01 16:02:00-05:00,RTRX,neutral
1108076.0,"Retrophin Sees Q4 Rev. ~$37M vs. Est. $35.9M, FY17 Rev. ~$134M vs. Est. $132M",2017-01-09 08:03:00-05:00,RTRX,neutral
1108077.0,"BMO Capital Initiates Coverage on Retrophin at Outperform, Announces $25.00 PT",2016-04-12 06:01:00-04:00,RTRX,neutral
1108078.0,Retrophin Sees FY2015 Sales $99.90M vs $98.90M Est,2016-01-11 08:12:00-05:00,RTRX,neutral
1108079.0,"JMP Securities Initiates Coverage on Retrophin at Market Outperform, Announces $30.00 PT",2015-11-02 07:38:00-05:00,RTRX,positive
1108080.0,"Avondale Partners Initiates Coverage on Retrophin at Outperform, Announces $39.00 PT",2015-05-15 09:20:00-04:00,RTRX,neutral
1108081.0,"Deutsche Bank Initiates Coverage on Retrophin at Buy, Announces $50.00 PT",2015-04-28 06:33:00-04:00,RTRX,neutral
1108082.0,"Leerink Swann Initiates Coverage on Retrophin at Outperform, Announces $48.00 PT",2015-04-02 08:45:00-04:00,RTRX,neutral
1108083.0,"Nomura Initiates Coverage on Retrophin at Buy, Announces $31.00 PT",2015-03-30 06:20:00-04:00,RTRX,neutral
1108084.0,"Retrophin Reports Prelim FY2014 Sales $28.30M, Announces Sparsentan Wins Orphan Drug Designation",2015-01-09 08:05:00-05:00,RTRX,positive
1108085.0,Retrophin Reports Q2 EPS of $(0.52),2014-08-12 07:02:00-04:00,RTRX,neutral
1108086.0,UPDATE: Retrophin Announces Bid to Acquire Clinuvel Pharmaceuticals ,2014-07-28 05:22:00-04:00,RTRX,neutral
1108087.0,Retrophin Sees FY2015 EPS $0.75-1.25; Raises FY2015 Sales Guidance from $36.0M-41.0M to $60.0M-70.0M,2014-05-29 16:43:00-04:00,RTRX,neutral
1108088.0,Retrophin Raises FY2014 Sales Guidance from $20.0M-22.0M to $30.0M-35.0M vs $20.0M Est,2014-05-29 16:42:00-04:00,RTRX,neutral
1108089.0,Retrophin Initiates Global Access for RE-024 in Pantothenate Kinase-Associated Neurodegeneration (PKAN) ,2014-05-12 08:07:00-04:00,RTRX,neutral
1108090.0,Retrophin Reports FY EPS of $(2.38),2014-03-27 09:13:00-04:00,RTRX,neutral
1108091.0,"Retrophin Sees FY2014 Sales $10.0M-12.0M, Sees FY14 Sales $19-21M",2014-02-12 18:12:00-05:00,RTRX,neutral
1108092.0,Transcept Pharmaceuticals Statement on the Withdrawal of Retrophin's $4.00/Share Offer ,2013-12-17 16:19:00-05:00,RTRX,neutral
1108093.0,"Retrophin Unveils New Clinical Development Candidate RE-034, An ACTH Analog ",2013-12-17 16:04:00-05:00,RTRX,neutral
1108094.0,Retrophin to Co-Sponsor Phase II Clinical Trial of Intranasal Oxytocin for Schizophrenia ,2013-12-12 07:24:00-05:00,RTRX,neutral
1108095.0,Retrophin to Acquire Kyalin Biosciences ,2013-12-12 07:21:00-05:00,RTRX,neutral
1108096.0,Retrophin Signs Exclusivity Agreement with Major Pharmaceutical Company to Negotiate License to a Product to be Developed for Autism and Schizophrenia ,2013-08-16 07:38:00-04:00,RTRX,positive
